Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 66Lymphoma, Large B-Cell, Diffuse 48Lymphoma 34Burkitt Lymphoma 28Lymphoma, Follicular 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasms 14Lymphoma, Non-Hodgkin 14Lymphoma, B-Cell 12Lymphoma, T-Cell, Peripheral 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Hodgkin Disease 9Lymphoma, B-Cell, Marginal Zone 8Leukemia 7Recurrence 6Prostatic Neoplasms, Castration-Resistant 6Multiple Myeloma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Neoplasm Metastasis 5Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoproliferative Disorders 4Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Immunoblastic Lymphadenopathy 4Ovarian Neoplasms 3Myasthenia Gravis 3Metastatic Castration-resistant Prostate Cancer 3Melanoma 3

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Prednisone × 1 year × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡